{"DataElement":{"publicId":"2778274","version":"1","preferredName":"Laboratory Procedure Serum Glutamic Pyruvic Transaminase Serum Glutamic Oxaloacetic Transferase Eligibility Determination Ind-2","preferredDefinition":"the yes/no indicator that asks whether a medical procedure has been performed that involves testing a sample of blood, urine, or other substance for Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transferase as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_SGPT_SGOT_EL_IN","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2778258","version":"1","preferredName":"Laboratory Procedure Serum Glutamic Pyruvic Transaminase Serum Glutamic Oxaloacetic Transferase Eligibility Determination","preferredDefinition":"information related to the medical procedure that involves testing a sample of blood, urine, or other substance for Serum Glutamic Pyruvic Transaminase, a test of liver function, human Glutamic-Pyruvate Transaminase (Alanine Aminotransferase Family) is pyridoxal phosphate-dependent enzyme involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis, and Serum Glutamic Oxaloacetic Transferase, test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferase (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) is pyridoxal phosphate-dependent enzyme involved in amino acid metabolism and in the urea and tricarboxylic acid cycles, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_SGPT_SGOT_ELIG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2778256","version":"1","preferredName":"SGPT (ALT) SGOT (AST) Eligibility Determination","preferredDefinition":"Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI):Activity measured as a test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferases (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. (NCI):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C25293:C25202:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alanine Aminotransferase","conceptCode":"C25293","definition":"A family of pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Alanine aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-alanine to alpha-ketoglutarate forming pyruvate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Aspartate Aminotransferase","conceptCode":"C25202","definition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55735293-83A3-6527-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-27","modifiedBy":"ONEDATA","dateModified":"2008-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55735293-83B4-6527-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-27","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"},{"publicId":"2811957","version":"1","longName":"Labs","context":"CTEP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104894","version":"1","longName":"GOG-0231D","context":"NRG"},{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"4104881","version":"1","longName":"GOG-0227G","context":"NRG"},{"publicId":"4104890","version":"1","longName":"GOG-0229L","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104891","version":"1","longName":"GOG-0229N","context":"NRG"},{"publicId":"10000281","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"10000282","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"4104929","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000276","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104930","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"10000275","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104915","version":"1","longName":"GOG-0255","context":"NRG"},{"publicId":"10000592","version":"1","longName":"GOG-0255","context":"NRG"},{"publicId":"10000591","version":"1","longName":"GOG-0255","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"},{"publicId":"4104901","version":"1","longName":"GOG-0286B","context":"NRG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"LAB_SGPT_SGOT_EL_IN","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"SGOT(AST) and SGPT(ALT) <=2.5","type":"Preferred Question Text","description":"SGOT(AST) and SGPT(ALT) <=2.5 x ULN or SGOT(AST) and SGPT(ALT) <5 x ULN if elevations are due to liver metastases.","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Are the SGOT and SGPT less than or equal to 2.5 x ULN","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Are SGOT (AST) and SGPT (ALT) less than or equal to 3 x ULN","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"SGOT (AST) and SGPT (ALT) >=3 x ULN or SGOT (AST) and SGPT (ALT) <=5 x ULN if elevations are due to liver metastases","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"SGOT (AST) and SGPT (ALT) <=3 x ULN or SGOT (AST) and SGPT (ALT) <=5 x ULN if elevations are due to liver metastases","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Is the AST and ALT less than or equal to 3.0 X ULN","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Is the AST and ALT less than or equal to 2.5 X ULN?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Is the AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 2","type":"Alternate Question Text","description":"Is AST(SGOT) and ALT(SGPT) less than or equal to 2.5 x ULN","url":null,"context":"NRG"},{"name":"NRG_CRF Text 3","type":"Alternate Question Text","description":"AST and ALT <3 x Upper Limit of Normal(ULN) within 30 days prior to registration on study?","url":null,"context":"NRG"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"AST (SGOT)/ALT (SGPT) <=3 x ULN","url":null,"context":"PBTC"},{"name":"CRF Text8","type":"Alternate Question Text","description":"ALT and AST is less than or equal to 3 x ULN within 14 days prior to step 2 registration","url":null,"context":"NRG"},{"name":"CRF Text 12","type":"Alternate Question Text","description":"ALT (SGPT) <= 5 x institutional ULN for patients with liver metastases","url":null,"context":"CTEP"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"AST (SGOT)/ALT (SGPT) <=1.5 x ULN","url":null,"context":"PBTC"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"AST (SGOT) <= 5 x institutional ULN for patients with liver metastases","url":null,"context":"CTEP"},{"name":"CRF Text9","type":"Alternate Question Text","description":"AST (SGOT) <=5 x institutional ULN for patients with liver metastases","url":null,"context":"CTEP"},{"name":"CRF Text10","type":"Alternate Question Text","description":"ALT (SGPT) <=5 x institutional ULN for patients with liver metastases","url":null,"context":"CTEP"},{"name":"CRF TEXT 12","type":"Alternate Question Text","description":"ALT and AST is less than or equal to 3 x ULN within 28 days prior to step 2 registration","url":null,"context":"NRG"},{"name":"PBTC_Text4","type":"Alternate Question Text","description":"ALT (SGPT) <=3 x institutional ULN","url":null,"context":"PBTC"},{"name":"CRF_Text_13","type":"Alternate Question Text","description":"Is the AST(SGOT)/ALT(SGPT) less than 2.5 X institutional upper limit of normal?","url":null,"context":"CTEP"},{"name":"PBTC-Text3","type":"Alternate Question Text","description":"AST (SGOT)/ALT (SGPT) <= 3 x institutional ULN","url":null,"context":"PBTC"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Is the patient's AST and ALT <= 5 x ULN?","url":null,"context":"CTEP"},{"name":"CRF TEXT 15","type":"Alternate Question Text","description":"ALT <= 2.5 x ULN within 14 days prior to registration","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Are the patient's AST and ALT less than or equal to 5 x ULN?","url":null,"context":"NRG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"55735D43-B97F-65E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-27","modifiedBy":"TSESU","dateModified":"2023-03-21","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}